NDAORALTABLET
Approved
Jan 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Mechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Clinical Trials (5)
A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions
Started May 2022
42 enrolled
Healthy Participants
A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time
Started Feb 2020
34 enrolled
Healthy Participants
Pharmacokinetic Effect of Evotaz/Microgynon Co-administration
Started Jul 2016
13 enrolled
HIV
Taste Properties of Atazanavir and Cobicistat
Started Dec 2014
6 enrolled
HIV in Adults
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
Started Apr 2013
64 enrolled
Human Immunodeficiency Virus Type 1 (HIV-1)
Loss of Exclusivity
LOE Date
Oct 6, 2032
80 months away
Patent Expiry
Oct 6, 2032